Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

Phase III Clinical Trial of Acetavance(TM) for the Treatment of Fever

Achieves Primary Endpoint

Phase III Clinical Trial of Omigard(TM) Completes Patient Enrollment

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the quarter ended March 31, 2008 and provided an update on the clinical development programs for its product candidates Acetavance(TM), an intravenous formulation of acetaminophen, and Omigard(TM), a topical antimicrobial gel.

The company announced that a Phase III clinical trial of Acetavance successfully met its primary endpoint of achieving a more rapid onset of action in the treatment of fever compared to oral acetaminophen. In addition, Cadence announced that it completed its goal of enrolling 1,850 patients in its Phase III clinical trial of Omigard for the prevention of catheter-related infections.

"We are very pleased with the outcome of our second Phase III clinical trial for the treatment of fever in adults. In addition to the positive data from our first Phase III clinical trial of Acetavance in fever announced earlier this year, we believe that the results of this study further strengthen the value proposition for Acetavance," said Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that there is a significant unmet need among patients and physicians in the hospital setting for a safe and effective treatment for pain and fever, particularly in cases where patients cannot take oral medication or require a mor
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... , ... leaders Earn Prestigious Parallels Partner Awards for innovation, branding, inspiration and growth at the ... ... , today announced the winners of its inaugural Partner Awards at the Parallels Summit ...
... , , ... ... ... ...
... a cruel, hereditary condition that leads to severe physical and ... are no treatments to slow down or stop it. ... not show symptoms until late in life. In a ... Stephen Ferguson and Fabiola Ribeiro of Robarts Research Institute at ...
... ... a business process consultant, life coach and self improvement veteran of more ... coaches to market their services, as well as an Ask-a-Coach corner where ... of information where coaches, clients and visitors may freely interact. ...
... ... ... ... ...
... proteins in premalignant oral lesions may predict oral ... SIBLINGs, or Small Integrin-Binding Ligand N-linked Glycoproteins, ... mineralize bone but can also spread cancer. SIBLINGs ... colon and prostate. "Several years ago we ...
Cached Medicine News:Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 2Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 2Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 4Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 5Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 6Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 7Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 8Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 9Health News:Protecting the brain from a deadly genetic disease 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 3Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 2Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 3Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 5Health News:SIBLING proteins may predict oral cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: